CAR-T cell therapy has emerged as an important therapeutic advancement in the management of relapsed or refractory haematological malignancies. However, treatment-associated immune dysfunction, prolonged cytopenias, B-cell aplasia, hypogammaglobulinemia and immunosuppressive therapy increase the risk of bacterial, viral and fungal infections. Antimicrobial prophylaxis plays a crucial role in infection prevention; nevertheless, variations in immune recovery and infection susceptibility make fixed-duration prophylactic strategies challenging. Prolonged antimicrobial exposure may also contribute to drug-related toxicities, drug interactions, antimicrobial resistance and disruption of the gut microbiome. This review examines the evolving landscape of infectious complications following CD19- and BCMA-directed CAR-T cell therapy, focusing on immune dysfunction, prophylactic antimicrobial strategies, infection-risk assessment and antimicrobial-associated medication-related challenges. Particular emphasis is placed on the clinical pharmacist's role in antimicrobial prescription review, dose optimisation, toxicity surveillance, drug interaction management and multidisciplinary collaboration. Furthermore, an integrated dynamic, pharmacist-led antimicrobial stewardship framework is proposed, incorporating baseline infection-risk assessment, longitudinal immune monitoring, antimicrobial optimisation and individualised prophylaxis continuation, modification or discontinuation. The proposed approach considers absolute neutrophil count, CD4+ T-cell recovery, immunoglobulin levels, infection history and immunosuppressive exposure to support informed clinical decisions. By integrating immune recovery with medication safety and antimicrobial stewardship, this framework may promote appropriate prophylaxis, minimise unnecessary antimicrobial exposure and improve supportive care. Prospective multicentre studies are required to validate its clinical applicability and determine its impact on infectious complications and patient outcomes.
Loading....